+18% vs analyst target · new source · 4 agree · 0 dissent
Why BUY: Q3 beat-and-raise (2026 EPS of at least $20.50); Morgan Stanley's top-ranked analyst reiterates Buy with a $529 target.
⚠ Medicare Advantage cost trends or policy changes could stall the turnaround the bulls are paying for.